[
  {
    "ts": null,
    "headline": "Why Moderna Stock Was So Healthy This Week",
    "summary": "The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine.  Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing the Spikevax coronavirus vaccine, was an uncharacteristically popular stock.  On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine.",
    "url": "https://finnhub.io/api/news?id=236d0ea14446f97d6e6da943ce878de002e84ad0f8ab778f47cfffc889cd6f2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751656074,
      "headline": "Why Moderna Stock Was So Healthy This Week",
      "id": 135755811,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine.  Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing the Spikevax coronavirus vaccine, was an uncharacteristically popular stock.  On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine.",
      "url": "https://finnhub.io/api/news?id=236d0ea14446f97d6e6da943ce878de002e84ad0f8ab778f47cfffc889cd6f2a"
    }
  }
]